Literature DB >> 28780942

Mast cell activation syndromes.

Cem Akin1.   

Abstract

Mast cell activation is common and possibly necessary for maintenance of survival. Disordered mast cell activation occurs when mast cells are pathologically overproduced or if their activation is out of proportion to the perceived threat to homeostasis. Mast cell activation syndrome refers to a group of disorders with diverse causes presenting with episodic multisystem symptoms as the result of mast cell mediator release. Despite introduction of diagnostic criteria and some advances in treatment in the last decade, many areas of mast cell activation syndrome are in need of research. This article reviews our current knowledge about the various types of mast cell activation disorders, their treatment, and areas of uncertainty in need of future investigation.
Copyright © 2017 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Mast cell; anaphylaxis; mast cell activation syndrome; mastocytosis; tryptase

Mesh:

Year:  2017        PMID: 28780942     DOI: 10.1016/j.jaci.2017.06.007

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  33 in total

Review 1.  The Role of KIT Mutations in Anaphylaxis.

Authors:  Elise Coulson; Sherry Zhou; Cem Akin
Journal:  Curr Allergy Asthma Rep       Date:  2019-04-26       Impact factor: 4.806

Review 2.  Mast cell activation in the context of elevated basal serum tryptase: genetics and presentations.

Authors:  Paneez Khoury; Jonathan J Lyons
Journal:  Curr Allergy Asthma Rep       Date:  2019-11-27       Impact factor: 4.806

Review 3.  Postural Orthostatic Tachycardia Syndrome: Prevalence, Pathophysiology, and Management.

Authors:  Adena Zadourian; Taylor A Doherty; Iwona Swiatkiewicz; Pam R Taub
Journal:  Drugs       Date:  2018-07       Impact factor: 9.546

4.  Can H2 -receptor upregulation and raised histamine explain an anaphylactoid reaction on cessation of ranitidine in a 19-year-old female? A case report.

Authors:  Susan J Allen; Paul L Chazot; C Jane Dixon
Journal:  Br J Clin Pharmacol       Date:  2018-04-18       Impact factor: 4.335

5.  Generalized pruritus relieved by NSAIDs in the setting of mast cell activation syndrome.

Authors:  Katrina Kesterson; Zachary Nahmias; Jonathan R Brestoff; Nancy D Bodet; Andrew Kau; Brian S Kim
Journal:  J Allergy Clin Immunol Pract       Date:  2018-03-23

6.  Microarray-Based Detection of Allergen-Reactive IgE in Patients with Mastocytosis.

Authors:  Dubravka Smiljkovic; Renata Kiss; Christian Lupinek; Gregor Hoermann; Georg Greiner; Nadine Witzeneder; Gerhard Krajnik; Franz Trautinger; Susanne Vrtala; Irene Mittermann; Michael Kundi; Bernd Jilma; Rudolf Valenta; Wolfgang R Sperr; Peter Valent
Journal:  J Allergy Clin Immunol Pract       Date:  2020-04-26

7.  Mast cell activation syndrome: Importance of consensus criteria and call for research.

Authors:  Peter Valent; Cem Akin; Patrizia Bonadonna; Karin Hartmann; Sigurd Broesby-Olsen; Knut Brockow; Joseph H Butterfield; Andreas Reiter; Jason Gotlib; Mariana Castells; Joshua D Milner; Melody C Carter; Hirsh Komarow; Deepti Radia; Animesh Pardanani; Karl Sotlar; Massimo Triggiani; Hans-Peter Horny; Michel Arock; Lawrence B Schwartz; Dean D Metcalfe
Journal:  J Allergy Clin Immunol       Date:  2018-06-19       Impact factor: 10.793

8.  Integrative analysis of somatic mutations and differential expression profiles in glioblastoma based on aging acceleration.

Authors:  Huize Wang; Shiyan Li; Hongxin Liu; Shiyu Bian; Wanjiang Huang; Chengzhong Xing; Yin Wang
Journal:  Int J Clin Exp Pathol       Date:  2021-05-15

9.  Mast cell disorders: Protean manifestations and treatment responses.

Authors:  Meng Chen; Alexander Kim; Bruce Zuraw; Taylor A Doherty; Sandra Christiansen
Journal:  Ann Allergy Asthma Immunol       Date:  2018-03-28       Impact factor: 6.347

Review 10.  Mast Cell-Biomaterial Interactions and Tissue Repair.

Authors:  Emily W Ozpinar; Ariana L Frey; Glenn Cruse; Donald O Freytes
Journal:  Tissue Eng Part B Rev       Date:  2021-01-21       Impact factor: 6.389

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.